^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

6P - RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study

Published date:
03/02/2023
Excerpt:
As of 05 Jan 2023 (data cutoff), 1 patient achieved CR, 4 patients achieved PR, 4 patients achieved SD, and only 1 patient achieved PD. The overall confirmed DCR was 90%....RC48-ADC showed a promising efficacy with a manageable safety profile in HER2-expressing mSDC patients who had failed at least one line of systemic chemotherapy.